Advancing urinary care

through intelligent design.

Clinical Evidence

We're proud that our innovation is backed by clinical evidence and case studies. Below are some of our clinical evidence and case study feedback.

Icon of a speech bubble with a star inside, on a teal circular background.

2026 - UK - PUBLICATION COMING SOON

Product evaluation at an NHS hospital looking at correct patient selection and quality of life outcomes.

Icon of a speech bubble with a star inside, on a teal circular background.

2026 - Italy - COMING SOON

Multi-centre study for long-term use of cymactive™ device for quality-of-life outcomes.

Icon of a speech bubble with a star inside, on a teal circular background.

2026 - Denmark - COMING SOON

A local study in Denmark to trial cymactive™ in comparison against recent sex life outcomes in association with Foley use.

Icon of a person pointing at a chalkboard or whiteboard.

2023: IN VITRO ENCRUSTATION STUDY

Outcome: The cymactive™ bladder management system showed that for the duration of the test (96h) it was able to resist encrustation and blockage by Pr. mirabilis in a glass bladder model system.

Icon of three people sitting at a table in a meeting or discussion.

2023 - User Engineering Trial

Outcome: Despite differing from a standard Foley Catheter, the device led to no ‘User Errors’ and only minor expected clarifications, indicating ease of use and clarity for Healthcare Professionals.

Icon of three human figures standing side by side, representing a group or community.

2018 - Argentina Study

Outcome: 80% showed good tolerance to the device, with 95% successful valve openings and closing of more than 1500 voids. 0% of urinary infections during this pilot.

Icon of a person speaking at a podium, representing a speaker or presenter.

2016: Safety and efficacy of a patient-controlled bladder management system for treating urinary retention in men: Bladder Management System

Outcome: This pilot study demonstrated it is potentially useful, convenient, and safe for appropriate patients. 95% successful valve openings and closing of more than 1400 voids and minimal leakage.